Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Harbour BioMed (HKEX: 02142) announced that partner Spruce Biosciences (Nasdaq: SPRB) separated its CRHX-101 antibody program into Adrenyx Biosciences, a wholly-owned subsidiary.
Adrenyx is expected to list on Nasdaq in the first half of 2027. Harbour BioMed expects equity interests in both companies after the planned pro rata distribution of Adrenyx shares to Spruce shareholders. Adrenyx secured an initial US$5 million through secured convertible notes; planned equity financing includes up to US$50 million from the notes investor, inclusive of notes funding. CRHX-101 is being developed for classic congenital adrenal hyperplasia. Next steps include nonclinical and manufacturing work, an FDA Investigational New Drug application and then clinical development.
Spruce Biosciences (SPRB) reported a third-quarter 2026 net loss of $24.0 million while advancing its planned TA-ERT regulatory submission. Loss widened from $8.2 million a year earlier, although loss per share narrowed to $8.51 from $14.58. Cash was $87.7 million at September 30; Spruce expects it to cover planned operations and debt obligations into the second half of 2027.
Spruce plans to seek accelerated approval for TA-ERT in MPS IIIB, a pediatric neurological disorder, in December 2026. Its second manufacturing qualification batch and confirmatory study initiation remain targeted for that month. An Avenue loan amendment makes up to $15 million available in Tranche 2, subject to conditions. Spruce also transferred CRHX-101 into subsidiary Adrenyx and expects to distribute its shares pro rata in the first half of 2027, subject to approvals and other conditions. The distribution is expected to be taxable for U.S. federal income tax purposes.
Spruce Biosciences (SPRB) transferred its CRHX-101 program to Adrenyx Biosciences effective November 6, 2026, ahead of a planned stock distribution. Spruce intends to distribute all Adrenyx shares pro rata to shareholders in the first half of 2027, creating two independent public companies. Completion requires Spruce board approval, an effective SEC registration statement and Nasdaq listing approval.
Adrenyx issued $5.0 million in secured convertible notes; the investor's anticipated funding of up to $50 million includes note funding. Spruce cannot use the note proceeds for its operations. The distribution is expected to be taxable for U.S. federal income tax purposes. Adrenyx plans nonclinical and manufacturing work before seeking FDA permission for human trials of CRHX-101 for classic congenital adrenal hyperplasia. Spruce plans a December 2026 TA-ERT marketing application and a potential 2027 U.S. launch, if approved.
Spruce Biosciences (Nasdaq: SPRB) will participate in the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026. CEO Javier Szwarcberg will join a fireside chat at 11:30 a.m. ET in Boston. A live webcast will be available, with an archived copy on the company’s website events section for approximately 90 days following the presentation.
Spruce Biosciences (SPRB) will participate in a fireside chat at the Craig-Hallum Biotech Catalyst Conference on October 22, 2026. Chief Executive Officer Javier Szwarcberg will represent the company. An archived webcast will be available in the events section of the company’s website for approximately 90 days following the live presentation.
Spruce Biosciences (SPRB) will present MPS IIIB natural history data at the Child Neurology Society Annual Meeting on October 15, 2026.
Study 250-902 tracks disease progression in children with severe, non-attenuated Sanfilippo Syndrome Type B without intervention. The poster examines cognition, motor function, communication and adaptive disease course. The meeting runs October 14–17 in Montréal, Canada; the poster will be available on the company website after presentation.
Spruce Biosciences (SPRB) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 2:00 p.m. ET in New York.
Chief Executive Officer Javier Szwarcberg, M.D., M.P.H., will deliver the presentation. A live webcast will be accessible online, and an archived replay will be available in the events section of the company’s website for approximately 90 days.
Spruce Biosciences (Nasdaq: SPRB) launched MPS3BStudy.com, an information and interest‑registration website for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB). The site covers disease basics, investigational tralesinidase alfa enzyme replacement therapy (TA-ERT), and details of a planned Expanded Access Program (EAP) and TrAnsform confirmatory study.
The TA-ERT EAP is an open-label U.S. program expected to enroll about 10 children with attenuated or severe MPS IIIB, while the TrAnsform randomized confirmatory study plans to enroll about 14 children with severe MPS IIIB. Both programs are expected to initiate as early as the fourth quarter of 2026.
Spruce Biosciences (Nasdaq: SPRB) reported successful completion of two pre-BLA meetings with the FDA supporting its plan to submit a biologics license application (BLA) in the fourth quarter of 2026 for tralesinidase alfa enzyme replacement therapy (TA-ERT) to treat Sanfilippo Syndrome Type B (MPS IIIB).
The FDA found Spruce’s chemistry, manufacturing and controls (CMC) analytical comparability strategies reasonable after technology transfer to a leading global biologics manufacturer and aligned with the overall content and format of the planned BLA, including integrated efficacy and safety summaries. Spruce has completed commercial-scale technology transfer, manufactured registrational drug product batches, and produced the first process performance qualification (PPQ) batch, with the second PPQ batch expected in Q4 2026. The FDA has maintained support for an accelerated approval pathway based on reduction of cerebrospinal fluid heparan sulfate non-reducing ends (CSF HS-NRE), with a confirmatory study allowed to start during BLA review. TA-ERT holds multiple U.S. expedited and orphan designations and may qualify for a rare pediatric disease priority review voucher if approved.
Spruce Biosciences (Nasdaq: SPRB) reported second quarter 2026 results and advanced its lead candidate tralesinidase alfa (TA-ERT) for mucopolysaccharidosis type IIIB (MPS IIIB). The company plans a BLA submission in Q4 2026, seeking FDA accelerated approval using CSF HS-NRE as a surrogate endpoint, and expects to initiate the FDA-requested TrAnsform confirmatory study in Q4 2026 in approximately 14 young children with severe MPS IIIB.
Spruce announced a $5.5 million strategic investment from Cure Sanfilippo Foundation and the National MPS Society to partially fund a U.S. Expanded Access Program enrolling about 10 patients, targeted to start in Q4 2026. Leadership was strengthened with the appointments of Adrian Quartel, M.D., as Chief Medical Officer and Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development.
Cash and cash equivalents were $96.3 million on June 30, 2026, up from $48.9 million at year-end 2025, which Spruce believes funds operations and debt obligations into the second half of 2027. Second quarter 2026 operating expenses were $16.5 million, and net loss was $16.2 million, or $(6.68) per share; six-month 2026 net loss was $28.5 million versus $16.1 million in the prior-year period.